
Caris Life Sciences, Inc.
HealthcareNASDAQ:CAI · NASDAQ Global Select
-$0.03 today
Vol 1.96M · Avg 2.67M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-93.2%
avg 0.5%
ROIC
4.5%
avg -20.0%
ROA
-47.8%
avg -22.2%
Analysis
ROIC is currently the strongest return metric at 4.5% versus its period average of -20.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David Dean Halbert | Chairman, Chief Executive Officer & Founder | $4.95M | — | 70 | $2.57M | 0.91% |
David Spetzler | President | $1.33M | — | 49 | $2.57M | 0.91% |
Brian J. Brille | Executive Vice Chairman & Executive Vice President | $1.20M | — | 64 | $230,303.00 | 0.08% |
J. Russel Denton | Senior Vice President, General Counsel & Secretary | $736,848.00 | — | 42 | $181,515.00 | 0.06% |
George W. Sledge Jr. | Executive VP & Chief Medical Officer | — | — | 74 | $17,729.00 | <0.01% |
Valeriy Domenyuk | Senior Vice President & Chief Technology Officer | — | — | — | — | — |
Andreas S. Tsukada | Senior VP, President of Japanese Operations & Head of International | — | — | — | — | — |
Luke Power | Senior Vice President, Chief Financial Officer & Chief Accounting Officer | — | — | 44 | $153,771.00 | 0.05% |
Matthew Oberley | Senior VP, Chief Clinical Officer & Pathologist-in-Chief | — | — | — | — | — |
Narendra Chokshi | Senior Vice President of Corporate Development | — | — | — | — | — |
Ginger Appleberry | Senior Vice President, Deputy General Counsel & Chief Compliance Officer | — | — | — | — | — |
Stephanie Thomas | Executive VP & Chief of Staff at Office of the CEO | — | — | — | $153,771.00 | 0.05% |
Jeremy O'Brien | Senior Vice President of Human Resources | — | — | — | — | — |
Jim Abraham | Senior VP & Chief Innovation Officer | — | — | — | — | — |
Milan Radovich | Senior Vice President & Chief Scientific Officer | — | — | — | — | — |
Jon Mark Harmon | Senior Vice President & Chief Operations Officer | — | — | — | $118,621.00 | 0.04% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$611,759.01
Sells
2
$1.65M
Net Sentiment
$1.04M
Net selling
Most Active
Power Luke Thomas
2 transactions
Analysis
Insiders reported 3 buys worth $611,759.01 and 2 sells worth $1.65M over the last 12 months. That adds up to net selling of $1.04M. Power Luke Thomas was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +3.8% | -5.4% (16yr)5 analysts |
| Revenue | N/A | N/A | +21.9% | +13.9% (16yr)5 analysts |
| Net Income | N/A | N/A | +6.3% | +24.3% (16yr)5 analysts |
| EBIT | N/A | N/A | +14.7% | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +21.9% over three years. Forward estimates point to Net Income at +24.3% (16yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector

Moderna, Inc.
NASDAQ:MRNA
$19.80B

Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.48B

Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.08B

Corcept Therapeutics Incorporated
NASDAQ:CORT
$8.90B

Cytokinetics, Incorporated
NASDAQ:CYTK
$8.73B

Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.24B
Merus N.V.
MRUS
$6.83B

Abivax S.A.
NASDAQ:ABVX
$6.33B

Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.06B

Atrium Therapeutics, Inc.
NASDAQ:RNA
$211.60M
Who manages CAI?
Caris Life Sciences, Inc. (CAI) lists 16 active executives. The top listed executive is George W. Sledge Jr., Executive VP & Chief Medical Officer.
Are CAI insiders buying or selling?
Recent insider activity shows net selling of $117.90M.
Explore More
Continue the stock analysis
Jump to another research area for this company.